BioNTech's Lung Cancer Gambit Meets Market Skepticism

BioNTech partners with Boehringer Ingelheim on a new lung cancer trial as investor confidence wanes due to mixed drug data and leadership changes.

BioNTech SE finds itself at a critical juncture in April 2026, balancing a bold new clinical alliance against a backdrop of mounting investor concerns. The company's strategic pivot to oncology, designed to offset declining COVID-19 vaccine revenue, is facing simultaneous tests in the lab and on the trading floor.

Investor sentiment has cooled noticeably, reflected in a share price of 77.90 euros—a drop of roughly 26 percent from its 52-week high. This pressure stems from a confluence of operational and political challenges. Mixed data for the oncology candidate gotistobart has been a particular drag. While a Phase 1 study showed a 54 percent reduction in the risk of death compared to chemotherapy, it was accompanied by a higher rate of severe side effects, casting doubt on its commercial future. Analysts at Leerink responded by slashing their price target from $113 to $94, citing diminished prospects for the drug's crucial Phase 3 trial.

A High-Stakes Clinical Collaboration

Amid this turbulence, BioNTech announced a significant new oncology partnership with Boehringer Ingelheim on April 9, 2026. The collaboration targets small cell lung cancer (SCLC), an aggressive disease accounting for 15 to 20 percent of all lung cancer cases where most patients relapse within months. The companies will launch a Phase-Ib/II study combining two investigational agents: Boehringer’s T-cell engager, obrixtamig, and BioNTech’s bispecific antibody, pumitamig, which is co-developed with Bristol Myers Squibb.

The rationale is to attack the cancer on complementary fronts. Obrixtamig directs immune cells against DLL3-expressing tumor cells, while pumitamig simultaneously blocks the PD-L1 immune checkpoint and inhibits blood vessel formation via VEGF-A. Early data for both candidates provide a foundation for optimism. Pumitamig, in a global Phase II first-line study combined with chemotherapy, achieved a confirmed objective response rate of 76.3 percent and a disease control rate of 100 percent. Obrixtamig showed a 68 percent response rate in its own Phase I study. The first patient in this new combination trial is slated for treatment in the second half of 2026.

External Pressures and Internal Reshuffling

Beyond clinical hurdles, broader macro pressures are adding to the uncertainty. New US tariffs of up to 100 percent on patented pharmaceutical imports pose a potential threat to future margins. While BioNTech management believes its transatlantic production setup with Pfizer for Comirnaty offers some protection, the policy remains a risk factor.

Internally, the planned departure of CEO U?ur ?ahin and CMO Özlem Türeci has unsettled some observers, a concern echoed by BMO Capital when it lowered its price target to $128. The company is moving to reinforce its oncology focus at a governance level. A shareholder vote scheduled for May 15, 2026, will seek to add two oncology specialists to the supervisory board, aiming to bolster oversight of BioNTech’s ambitious pipeline.

That pipeline is central to the company's future. BioNTech aims to have 15 ongoing Phase 3 oncology trials by the end of 2026, with several key data readouts expected. This push is vital as the firm forecasts a significant decline in COVID-19 vaccine revenue for the year, projecting total 2026 sales between 2.0 and 2.3 billion euros.

Financial Fortitude for a Long Transition

Despite the near-term headwinds, BioNTech’s balance sheet provides a substantial buffer for its strategic transformation. The company ended 2025 with a massive liquidity reserve of approximately 17.2 billion euros, funding the costly clinical development required to build a diversified product portfolio by 2030.

The path forward is now clearly charted between two poles: the promising but perilous science of next-generation cancer therapies and the impatient reality of financial markets. The coming months will reveal whether the early promise of assets like pumitamig can outweigh the disappointments of others and convince investors that BioNTech’s post-pandemic reinvention is on track.